## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.65 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. The Future of Bone Sonometer Market 2032 Industry Forecast**
- Source: openPR.com | 20251229T072740 | Bullish | Relevance: 100%
- The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.

**2. Skin Rejuvenation Devices Market Forecast Report: Strategic Insights, Expansion Opportunities and Key Players to 2032 |Cutera Inc., Hologic, Inc., Lutronic Corporation**
- Source: openPR.com | 20251229T060825 | Somewhat-Bullish | Relevance: 94%
- The global skin rejuvenation devices market is projected to grow from US$2,227.4 million in 2022 to exhibit a CAGR of 9.5% during 2022-2030, driven by rapid innovation and shifting regional dynamics. This report offers strategic insights, segmentation by type, application, and region, and profiles key industry players like Cutera Inc. and Hologic Inc. It also highlights investment hotspots and production/consumption patterns to help stakeholders capitalize on upcoming opportunities.

**3. Smart Oncology: 5 Stocks Chasing the $317B Prize**
- Source: Morningstar | 20251231T120849 | Somewhat-Bullish | Relevance: 92%
- The precision oncology market is rapidly expanding, driven by advancements in biomarker-guided therapies and AI. This article highlights five key players—Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc.—that are at the forefront of this $317 billion industry. These companies are developing innovative solutions for cancer diagnosis and treatment, offering new hope for personalized and effective care.

**4. Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment**
- Source: Finviz | 20251230T174600 | Neutral | Relevance: 55%
- Abbott Laboratories (ABT) has received FDA approval for its Volt™ PFA System, designed to treat patients with atrial fibrillation (AFib). This system will soon be commercially available in the U.S. and is already expanding in the EU after CE Mark approval. The approval follows the VOLT-AF IDE study, which demonstrated the system's safety and effectiveness for both paroxysmal and persistent AFib.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.6B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 14.9 |
| Current P/E | 16.3 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.1% to 0.1% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 49. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.08% (CS: 63) | Neutral |
| RSI_14 | 48.8 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.49
- **Stop Loss:** $73.95 (0.7% risk)
- **Target:** $75.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2666
- **Position Value:** $198,590.34
- **Portfolio %:** 198.59%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*